Showing results (1401-1410 of 2,232) with videos related to
Sort By:
Pageof 224
Cancer Biotherapy & Radiopharmaceuticals|September 30, 2004
Alemtuzumab in peripheral T-cell malignanciesClaire DeardenCancer Biotherapy & Radiopharmaceuticals|September 30, 2004
Influence of glutathione depletion on plasma membrane cholesterol esterification and on Tc-99m-sestamibi and Tc-99m-tetrofosmin uptakes: a comparative study in sensitive U-87-MG and multidrug-resistant MRP1 human glioma cellsNathalie Le Jeune, Nathalie Perek, Delphine Denoyer, et al.Cancer Biotherapy & Radiopharmaceuticals|September 30, 2004
Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopeniaRussell Schilder, Arturo Molina, Nancy Bartlett, et al.Cancer Biotherapy & Radiopharmaceuticals|October 27, 2005
A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensityDavid R Minor, Michael T Madland, Mohammed Kashani-Sabet, et al.Cancer Biotherapy & Radiopharmaceuticals|October 27, 2005
Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9Shakeel Modak, Hong Fen Guo, John L Humm, et al.Cancer Biotherapy & Radiopharmaceuticals|October 27, 2005
Convenient solid-phase synthesis of diethylenetriaminepenta-acetic acid (DTPA)- conjugated cyclic RGD peptide analoguesWei Wang, John S McMurray, Qingping Wu, et al.Cancer Biotherapy & Radiopharmaceuticals|March 2, 2010
Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)Andres Forero-Torres, Jatin Shah, Tina Wood, et al.Cancer Biotherapy & Radiopharmaceuticals|March 2, 2010
Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunityYufeng Xie, Ou Bai, Haifeng Zhang, et al.Cancer Biotherapy & Radiopharmaceuticals|March 2, 2010
Neoadjuvant immunotherapy enhances radiosensitivity through natural killer cell activationChau-Hwa Chi, Yu-Shan Wang, Chieh-Han Yang, et al.Cancer Biotherapy & Radiopharmaceuticals|December 23, 2009
Dosimetric study of Cs-131, I-125, and Pd-103 seeds for permanent prostate brachytherapyRuijie Yang, Junjie Wang, Hongzhi ZhangPageof 224